In breast cancer, overexpression of the proto‐oncogene HER2 leads to lipogenic reprogramming, including upregulation of DGAT enzymes, further implicating their involvement in oncogenic processes [33, 36]. The gene discussed is ERBB2; the disease is breast carcinoma.